- Email: [email protected]
84 A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma
84 - A population-based competing-risks analysis of survival after nephrectomy for renal ... Page 1 of 1
e84 A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma Bianchi M.1, Sun M.2, Schmitges J.3, Hanna N.2, Karakiewicz P.I.2 1Vita-Salute
San Raffaele University, Urologic Research Institute, Dept. of Urology, Milan, Italy, Prognostics and Health Outcomes Unit, University of Montreal Health Center, Dept. of Urology, Montreal, Canada, 3Martini-Clinic, Prostate Cancer Center, Dept. of Urology, Hamburg, Germany 2Cancer
INTRODUCTION & OBJECTIVES: Competing cause of mortality has been examined in patients with localized renal cell carcinoma (RCC). However the effect of tumor grade has not been accounted for. We reassessed this topic in all RCC stages integrating tumor grade. MATERIAL & METHODS: The Surveillance, Epidemiology, and End Results (SEER) database was used to identify 42090 patients treated with NT between years 1988 and 2008. Patients were stratified in 32 strata according to age groups (≤59, 60-69, 70-79, and ≥80 years), Fuhrman grade (I-II vs. III-IV) and American Joint Committee on Cancer (AJCC) stage which resulted in a total of 32 combinations. Competing risk Poisson analyses were performed to simultaneously assess the rates of CSM and OCM at 5 years after nephrectomy.
RESULTS: CONCLUSIONS: Our study provides a valuable graphical aid for prediction of CSM, and OCM, according to patient age, disease stage and grade in patients treated with NT for RCC, and this can help clinicians to better stratify the risk-benefit ratio of NT.
file://F:\RamShankar\April\04-05-12\Cip\Sour\84.html
4/6/2012
e84 A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma Bianchi M.1, Sun M.2, Schmitges J.3, Hanna N.2, Karakiewicz P.I.2 1Vita-Salute
San Raffaele University, Urologic Research Institute, Dept. of Urology, Milan, Italy, Prognostics and Health Outcomes Unit, University of Montreal Health Center, Dept. of Urology, Montreal, Canada, 3Martini-Clinic, Prostate Cancer Center, Dept. of Urology, Hamburg, Germany 2Cancer
INTRODUCTION & OBJECTIVES: Competing cause of mortality has been examined in patients with localized renal cell carcinoma (RCC). However the effect of tumor grade has not been accounted for. We reassessed this topic in all RCC stages integrating tumor grade. MATERIAL & METHODS: The Surveillance, Epidemiology, and End Results (SEER) database was used to identify 42090 patients treated with NT between years 1988 and 2008. Patients were stratified in 32 strata according to age groups (≤59, 60-69, 70-79, and ≥80 years), Fuhrman grade (I-II vs. III-IV) and American Joint Committee on Cancer (AJCC) stage which resulted in a total of 32 combinations. Competing risk Poisson analyses were performed to simultaneously assess the rates of CSM and OCM at 5 years after nephrectomy.
RESULTS: CONCLUSIONS: Our study provides a valuable graphical aid for prediction of CSM, and OCM, according to patient age, disease stage and grade in patients treated with NT for RCC, and this can help clinicians to better stratify the risk-benefit ratio of NT.
file://F:\RamShankar\April\04-05-12\Cip\Sour\84.html
4/6/2012